Research
Hormonal
Phentermine-topiramate combination therapy reduces the incidence of type 2 diabetes by 70% in prediabetic patients, demonstrating the power of significant weight loss via pharmacological means.
For those with prediabetes and metabolic syndrome, ask your doctor about phentermine-topiramate. It has shown a 70% reduction in diabetes incidence, highlighting that significant weight loss via medication is a viable and powerful preventive tool.
GoodSupportsHIGH confidence
Este estudio muestra una reducción de 70% de este fenómeno, inédito en intervenciones farmacológicas, lo cual pone un acento otra vez en la importancia del control de peso en la prevención de la diabetes.
Why this rating
Based on a specific cited study (Garvey et al.) showing 70% reduction.
Source
La prevención de la diabetes tipo 2. Muchas aristas y el peso como cuestión central
Elvio Bueno · Revista Virtual de la Sociedad Paraguaya de Medicina Interna · 2015
DOI 10.18004/rvspmi/2312-3893/2015.02(01)08-010
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Structured lifestyle interventions targeting a 5% body weight loss through diet and exercise reduce the incidence of type 2 diabetes by approximately 55% over five years, outperforming pharmacological interventions like metformin.Strong
- Weight loss exceeding 15% via bariatric surgery can reverse type 2 diabetes and is superior to conservative treatment for reducing incidence in individuals with BMI > 35 kg/m².Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →